Phase I Trial of Weekly Short Infusion of Single Agent Docetaxel in Patients with Advanced NSCLC/MBC
碩士 === 國立成功大學 === 臨床藥學研究所 === 88 === Purpose: Docetaxel (Taxoterea) is a novel semisynthetic antineoplastic agent that has been shown to be active in the treatment of solid tumor. The recommended dose used clinically is 60-100 mg/m2 infusion over 1 hr every 3 weeks. Recent clinical trials with pacli...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2000
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/21893970106874355013 |